Dr Reddy's Laboratories Ltd has scheduled its 42nd Annual General Meeting (AGM) for Thursday, July 23, 2026, at 11:00 a.m. IST through video conferencing. The Board of Directors has recommended a final dividend of ₹8 per equity share of the face value of ₹1 each for the financial year ended March 31, 2026. The dividend, if declared, will be paid on or before July 30, 2026, to members whose names appear on the Register of Members as of the end of the day on July 10, 2026.

The Notice and Integrated Annual Report for Financial Year 2025-26 were sent electronically on June 30, 2026. The AGM will transact ordinary business, including the adoption of audited financial statements for the financial year ended March 31, 2026. Shareholders will consider the re-appointment of Mr. K Satish Reddy, Director, who retires by rotation. The meeting will also seek approval to appoint M/s. Deloitte Haskins & Sells, LLP, as Statutory Auditors for a period of five consecutive years, replacing M/s. S. R. Batliboi & Associates LLP. The proposed audit fee for the financial year ending March 31, 2027, is ₹8,86,00,000 plus applicable taxes.

Special business includes the re-appointment of Dr. K P Krishnan as an Independent Director for a second term of five consecutive years effective from January 7, 2027, to January 6, 2032. Additionally, the appointment of Mr. Srikanth Velamakanni as an Independent Director for a term of five years effective from July 1, 2026, to June 30, 2031, will be put to vote. The company also seeks ratification for the remuneration payable to cost auditors, M/s. Sagar & Associates, amounting to ₹9,00,000 plus applicable taxes for the financial year ending March 31, 2027.

E-voting for the AGM commences on July 19, 2026, at 9:00 a.m. IST and concludes on July 22, 2026, at 5:00 p.m. IST. The cut-off date to determine shareholder eligibility for voting and dividend entitlement is July 16, 2026. The facility for attending the AGM virtually will be available for 1,000 members on a first-come, first-served basis, excluding large shareholders, promoters, and institutional investors.

Key AGM Dates and Details

The company has stated that the notice and the Integrated Annual Report have been sent electronically to members. Physical copies have not been dispatched. Shareholders can access the documents on the company's website.

Dr Reddy's Laboratories Ltd filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, reporting a standalone turnover of ₹20,102 crore. The pharmaceutical major committed to achieving net zero greenhouse gas emissions across its value chain by FY2045, a target approved by the Science Based Targets initiative (SBTi) during FY26. Additionally, the company aims for carbon neutrality in its direct operations by 2030. Exports contributed 68% of the total turnover, while 71% of input materials were sourced locally from within India.

The company detailed its environmental performance, highlighting the elimination of coal from its operational fuel mix. In FY26, Dr Reddy's completed a multi-year fuel transition, converting all primary operating boilers across its manufacturing network to biomass, briquettes, or piped natural gas. This initiative contributed to a reduction in Scope 1 and Scope 2 emissions. The company reported a decrease in total energy consumption to 46,49,832 GJ from 47,53,823 GJ in the previous year, with energy intensity improving to 13.8 GJ/₹ Million.

Financial and Operational Metrics

Dr Reddy's operations span pharmaceutical development, manufacturing, and sales, which account for 100% of its turnover. The report indicates that 71.5% of procurement was directly sourced from within the country, while 5.3% was sourced directly from MSMEs or small producers.

Environmental Performance

Water consumption stood at 19,56,215 kilolitres, with a water intensity of 5.82 KL/₹ Million. The company has implemented Zero Liquid Discharge facilities across 16 global manufacturing facilities. The report also noted that Dr Reddy's is a water-positive company since FY2023.

Social and Governance Highlights

The company employed 36,726 permanent and other-than-permanent employees as of the end of FY26. Women constituted 23.8% of the total workforce. The report noted that 43% of new launches in priority markets were first-to-market, exceeding the company's target of 40% by 2030. Dr Reddy's has set a goal to serve 1.5 billion patients by 2030. Regarding governance, the company stated that it received no fines or penalties from regulatory agencies during the financial year.